secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001193125-26-118699
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman
--------------------------------------------------------------------------------

- Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
- Three directors (Munshi, Goldfischer, Dallas) resigned March 23; not due to disagreements.
- New directors: Cameron Turtle (CEO, Spyre Therapeutics) and Mike Landsittel (ex-CFO, Blueprint Medicines).
- Peter Harwin named Chairman of the Board.
- Jarrett receives $695k base salary, 55% target bonus, 500k RSUs and 1.5M stock options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526118699/0001193125-26-118699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526118699/dmra-20260320.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-118699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer